

1/16





FIG. 1A



g1ZD-GFP

<i>env</i>	<i>IRES</i>
... AGAGTACGAGCCATAGATAACGTTACTGGCC ...	
<i>IRES</i>	<i>GFP</i>
... CACGATAATACCATGGCCATTCGAACAAAGG ...	
<i>GFP</i>	<i>MLV NONCODING</i>
... CTGTACAAGTAGCGGCCGCGCCATAGATAAA ...	

g1ZD-hygro

<i>env</i>	<i>IRES</i>
... AGAGTACGAGCCATAGATAACGTTACTGGCC ...	
<i>IRES</i>	<i>hygromycin^R</i>
... CACGATAATACCATGGCCATTCGAACCGCGA ...	
<i>hygromycin^R</i>	<i>MLV NONCODING</i>
... TGGGGGCGCGCCATAGATAAAATAAAAGAT ...	

FIG. 1B

20110108-011001

2/16




FIG. 2A




FIG. 2B

10045178-01102

3/16




FIG. 3A




FIG. 3B

20110101 08:50:00




FIG. 4

5/16

Percent of Cells Transduced
(by FACS Analysis)




FIG. 5

Infection Number





FIG. 6A

Infection Number



6/16




FIG. 6B

2017-07-20 14:54:00

7/16



Negative Control
group

Experimental
group

RAT NMU BREAST CANCER CELL INJECTION
 (INITIAL INOCULUM: 2×10^6 CELLS)

ESTABLISHMENT OF TUMORS (APPROX. 4 WEEKS)

g1ZD-GFP VIRUS INJECTION
 (1×10^4 INFECTIOUS UNITS IN $100 \mu\text{l}$)



FACS ASSAY

FACS ASSAY

FACS ASSAY






FIG. 7



9/16




FIG. 9A

20170103 13:54:00

10/16

20170327




FIG. 9B




FIG. 10




FIG. 11

13/16




FIG. 12




FIG. 13




FIG. 14







FIG. 15

15/16**FIG. 16A****FIG. 16B**

10045178.01102

16/16

ZE-GFP



ZV-A-GFP






FIG. 17

WILD TYPE MLV ENVELOPE



ZDAH-emd



ZBAH-emd




FIG. 18

10045178.01102